Last reviewed · How we verify
Instilled 1% Lidocaine
At a glance
| Generic name | Instilled 1% Lidocaine |
|---|---|
| Also known as | Lidocaine |
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections (PHASE4)
- Effect of Three Different Postcesarean Analgesic Techniques on QbsQor-10 Score (NA)
- The PRICE Trial: Pain Reduction for Intrauterine Contraception Experiment (PHASE2)
- Lung-Resident Memory Th2 Cells in Asthma (NA)
- Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder (PHASE4)
- Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection (NA)
- Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Instilled 1% Lidocaine CI brief — competitive landscape report
- Instilled 1% Lidocaine updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI